Literature DB >> 6687960

Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit.

R Pescador, M Mantovani, G Prino, M Madonna.   

Abstract

An extensive study of the pharmacokinetics and the pharmacokinetics of the profibrinolytic activity of Defibrotide (D) in the rabbit has been made. a two compartment model was used to describe D's pharmacokinetics. The parameters of drug disposition and the rate constant of release from tissues to central compartment were closely dose-dependent. The dose-response curves for elimination parameters were powers with a negative exponent indicating considerable saturation of this process. As a consequence, the T1/2, Co and AUC were also dose-dependent, as were the parameters describing the decrease in profibrinolytic activity in the blood stream.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6687960     DOI: 10.1016/0049-3848(83)90391-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

1.  Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion.

Authors:  F Pellegatta; Y Lu; A Radaelli; M R Zocchi; E Ferrero; S Chierchia; G Gaja; M E Ferrero
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 2.  The use of defibrotide in blood and marrow transplantation.

Authors:  Paul G Richardson; Enric Carreras; Massimo Iacobelli; Bijan Nejadnik
Journal:  Blood Adv       Date:  2018-06-26

3.  Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man.

Authors:  S Coccheri; G Biagi; C Legnani; B Bianchini; F Grauso
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock.

Authors:  H Bitterman; D J Lefer; A M Lefer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

5.  Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion.

Authors:  A M Lefer; N Aoki; D Mulloy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-03       Impact factor: 3.000

6.  New in vivo model to assess venous endothelial cell functions. Effect of defibrotide.

Authors:  T Di Perri; F Laghi Pasini; C Frigerio; P L Capecchi; G L Messa; M Franchi; F Landini; A Burresi; A Ghezzi; L Ceccatelli
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.

Authors:  K J Palmer; K L Goa
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

8.  The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits.

Authors:  W Paul; P Gresele; S Momi; G Bianchi; C P Page
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

9.  Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion.

Authors:  C Thiemermann; G R Thomas; J R Vane
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

10.  Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart.

Authors:  P Löbel; K Schrör
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.